Skip to main content
Premium Trial:

Request an Annual Quote

Montreal Heart Institute Developing Cardiac Screening Panel for GnuBio Sequencer

NEW YORK (GenomeWeb News) — GnuBio said today that it is collaborating with the Montreal Heart Institute to develop a genetic panel that will run on the GnuBio platform and predict the risk of sudden cardiac death.

The partners plan to use GnuBio's microfluidics-based sequencing system to develop and validate a set of genes related to sudden cardiac death. "The result will be a clinically validated test the can be used to assess the risk of SCD in susceptible patients on a sequencing platform that will significantly reduce the time from patient to result," the company said in a statement.

As reported by GenomeWeb Daily News sister publication In Sequence, GnuBio plans to launch its sequencer commercially in the second quarter of this year. The system will have a list price of $50,000 and the turnaround time for a targeted sequencing run is expected to be around two hours.

The Montreal Heart Institute is an early-access customer for the GnuBio sequencer. It received the system last summer.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.